Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CTKB 
Cytek Biosciences Inc (CTKB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: CTKB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.12
1 Year Target Price $5.12
| 1 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.22% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 525.44M USD | Price to earnings Ratio - | 1Y Target Price 5.12 |
Price to earnings Ratio - | 1Y Target Price 5.12 | ||
Volume (30-day avg) 6 | Beta 1.36 | 52 Weeks Range 2.37 - 7.63 | Updated Date 09/12/2025 |
52 Weeks Range 2.37 - 7.63 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.27% | Operating Margin (TTM) -23.3% |
Management Effectiveness
Return on Assets (TTM) -3.77% | Return on Equity (TTM) -1.67% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 287091203 | Price to Sales(TTM) 2.68 |
Enterprise Value 287091203 | Price to Sales(TTM) 2.68 | ||
Enterprise Value to Revenue 1.46 | Enterprise Value to EBITDA -133.96 | Shares Outstanding 127224000 | Shares Floating 108730530 |
Shares Outstanding 127224000 | Shares Floating 108730530 | ||
Percent Insiders 9.24 | Percent Institutions 63.36 |
Upturn AI SWOT
Cytek Biosciences Inc
Company Overview
History and Background
Cytek Biosciences Inc. was founded in 2006. It has focused on advancing cell analysis by developing innovative flow cytometry solutions. The company went public in 2021.
Core Business Areas
- Cell Analysis Instruments: Develops and manufactures cell analysis instruments that utilize full spectrum cytometry for advanced cell analysis.
- Reagents and Consumables: Offers a range of reagents and consumables used in flow cytometry experiments.
- Services and Support: Provides customer support, training, and application services for its instruments and reagents.
Leadership and Structure
Wenbing (Wayne) Ding is the CEO of Cytek Biosciences Inc. The company has a typical corporate structure with departments focused on R&D, sales, marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Aurora Cytometer: A full spectrum flow cytometer that offers high resolution and sensitivity. Competitors include BD Biosciences, Thermo Fisher Scientific, and Beckman Coulter. Market Share data specific to Aurora not available, but considered a key driver in Cytek's overall growth in flow cytometry. Likely top 3 among similar instruments.
- Northern Lights Cytometer: A more compact and affordable full spectrum flow cytometer, targeting a broader range of research labs. Competitors include BD Biosciences, Thermo Fisher Scientific, and Beckman Coulter. Market Share data specific to Northern Lights not available, but considered a high volume instrument that lowers the barrier to entry for full spectrum flow cytometry.
- ECHO Reagents: A reagent line designed to work synergistically with their cytometers. Competitors include BD Biosciences, Thermo Fisher Scientific, and BioLegend. Revenue contribution is secondary to instrument sales.
Market Dynamics
Industry Overview
The cell analysis market is growing, driven by advancements in immunology, drug discovery, and personalized medicine. Flow cytometry is a key technology in this market.
Positioning
Cytek is positioned as an innovator in full spectrum flow cytometry, offering high-performance instruments and expanding its reagent offerings. Its competitive advantage lies in its advanced technology and unique optical design.
Total Addressable Market (TAM)
The flow cytometry market is estimated to be worth billions of dollars, with projections for continued growth. Cytek is well-positioned to capture a significant share of this TAM through its innovative products and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Innovative full spectrum cytometry technology
- High-resolution and sensitivity instruments
- Strong brand reputation
- Expanding reagent portfolio
- Experienced management team
Weaknesses
- Relatively small market share compared to established players
- Dependence on research and development for continued innovation
- Limited sales and marketing reach compared to larger competitors
- Pricey instruments may limit adoption by smaller labs
Opportunities
- Expanding applications of flow cytometry in drug discovery and clinical diagnostics
- Increasing demand for high-performance cell analysis instruments
- Growing adoption of full spectrum cytometry
- Strategic partnerships with pharmaceutical and biotechnology companies
- Penetration into emerging markets
Threats
- Intense competition from established players
- Technological advancements by competitors
- Price pressures in the market
- Changes in regulatory requirements
- Economic downturn affecting research funding
Competitors and Market Share
Key Competitors
- BDX
- TMO
- BEC
Competitive Landscape
Cytek competes primarily on technology differentiation, while larger companies like BD and Thermo Fisher have broader product portfolios and established customer bases. Cytek needs to demonstrate superior performance for labs to switch over.
Major Acquisitions
Immudex ApS
- Year: 2021
- Acquisition Price (USD millions): 178
- Strategic Rationale: Expanded Cytek's reagent portfolio and enabled entry into adjacent markets related to immune monitoring and diagnostics.
Growth Trajectory and Initiatives
Historical Growth: Cytek has experienced substantial revenue growth in recent years driven by increased adoption of full spectrum flow cytometry. They are rapidly growing due to product differentiation and increasing customer base.
Future Projections: Analysts project continued revenue growth for Cytek, driven by expanding applications of full spectrum cytometry and strategic partnerships.
Recent Initiatives: Recent initiatives include expanding the reagent portfolio, strengthening sales and marketing efforts, and forming collaborations with key opinion leaders. Further initiatives involve expansion of production and distribution capabilities.
Summary
Cytek Biosciences is a growing company specializing in cell analysis solutions, particularly flow cytometry. Its innovative full spectrum technology sets it apart from competitors, but it has less market share to date compared to larger established players. Continued investment in research and development, strategic partnerships, and effective marketing are crucial for sustained growth. Economic uncertainty and technology leapfrogging remain potential concerns.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data can shift quickly and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cytek Biosciences Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2021-07-23 | President, CEO & Chairman of the Board Dr. Wenbin Jiang Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 688 | Website https://cytekbio.com |
Full time employees 688 | Website https://cytekbio.com | ||
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. It also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. In addition, the company offers automated micro-sampling system and automated sample loader system, an automated loaders designed to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. It serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in Europe, Latin America, and the Middle East countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.